The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ
transplantation and works by blocking the activity of T effector cells but preserving T
regulatory cells, as well as by inducing autophagy (protein degradation), will be effective
in IBM to slow or stabilize disease progression, helping to maintain patient function and
independence. This phase III trial will confirm pilot data showing statistically significant
clinical outcomes.